Specific inhibition of the classical complement pathway with an engineered single-chain Fv to C1q globular heads decreases complement activation by apoptotic cells
Authors:
- Hee Young HwangHHHee Young Hwang
- Robert J. BoackleRBRobert J. Boackle
- 1 May 2010
- journal article
- Published by Elsevier in Immunobiology
- Vol. 215 (5) , 395-405
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Complement Factor H Binds to Denatured Rather than to Native Pentameric C-reactive ProteinJournal of Biological Chemistry, 2008
- C4b-Binding Protein Is Present in Affected Areas of Myocardial Infarction during the Acute Inflammatory Phase and Covers a Larger Area than C3PLOS ONE, 2008
- Highly specific inhibition of C1q globular-head binding to human IgG: A novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragmentMolecular Immunology, 2008
- The connection between C‐reactive protein and atherosclerosisAnnals of Medicine, 2008
- Alterations of the classic pathway of complement in adipose tissue of obesity and insulin resistanceAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- The Factor H Variant Associated with Age-related Macular Degeneration (His-384) and the Non-disease-associated Form Bind Differentially to C-reactive Protein, Fibromodulin, DNA, and Necrotic CellsJournal of Biological Chemistry, 2007
- Complement susceptibility in glutamine deprived breast cancer cellsCell Division, 2007
- A common site within factor H SCR 7 responsible for binding heparin, C‐reactive protein and streptococcal M proteinEuropean Journal of Immunology, 2003
- C1 inhibitor removes the entire C1qr2s2 complex from anti‐C1Q monoclonal antibodies with low binding affinitiesImmunology, 1998
- Structural studies on human Clq: Non-covalent and covalent subunitsImmunochemistry, 1972